MX2023013021A - Inhibicion de trampas extracelulares. - Google Patents
Inhibicion de trampas extracelulares.Info
- Publication number
- MX2023013021A MX2023013021A MX2023013021A MX2023013021A MX2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A MX 2023013021 A MX2023013021 A MX 2023013021A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibition
- tse
- formation
- extracellular traps
- methods
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 abstract 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 abstract 1
- 229960002173 citrulline Drugs 0.000 abstract 1
- 235000013477 citrulline Nutrition 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003979 eosinophil Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención proporciona procedimientos para la inhibición de la formación de trampa extracelular de eosinófilos (EET). En particular, la invención proporciona anticuerpos o fragmentos de unión de los mismos dirigidos contra epitopos que contienen citrulina, para su uso en procedimientos para inhibir o detectar la formación de EET. Los procedimientos pueden ser para el diagnóstico, tratamiento o prevención de cualquier enfermedad o afección que incluya una patología asociada a EET.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21172160.0A EP4085973A1 (en) | 2021-05-04 | 2021-05-04 | Inhibition of eosinophil extracellular traps |
| GB202111541 | 2021-08-11 | ||
| PCT/EP2022/061970 WO2022233931A1 (en) | 2021-05-04 | 2022-05-04 | Inhibition of eosinophilic traps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013021A true MX2023013021A (es) | 2024-02-12 |
Family
ID=81392799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013021A MX2023013021A (es) | 2021-05-04 | 2022-05-04 | Inhibicion de trampas extracelulares. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250084154A1 (es) |
| EP (1) | EP4333981A1 (es) |
| JP (1) | JP2024521638A (es) |
| KR (1) | KR20240005856A (es) |
| AU (1) | AU2022270356A1 (es) |
| CA (1) | CA3215452A1 (es) |
| IL (1) | IL308223A (es) |
| MX (1) | MX2023013021A (es) |
| WO (1) | WO2022233931A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4442705A1 (en) | 2023-04-03 | 2024-10-09 | Citryll B.V. | Dosage |
| GB202318703D0 (en) | 2023-12-07 | 2024-01-24 | Citryll B V | Diagnostic agent |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
| ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| NO2294086T3 (es) | 2008-06-04 | 2018-02-10 | ||
| HUE033438T2 (en) | 2008-09-26 | 2017-11-28 | Ucb Biopharma Sprl | Biological products |
| WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| EP2332987A1 (en) | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
| WO2016092082A1 (en) | 2014-12-11 | 2016-06-16 | Modiquest B.V. | Method for the treatment of idiopathic pulmonary fibrosis |
| MX2021001902A (es) | 2018-08-21 | 2021-05-27 | Citryll B V | Anticuerpos que se unen a histona 2a y/o 4 citrulinada. |
-
2022
- 2022-05-04 KR KR1020237041716A patent/KR20240005856A/ko active Pending
- 2022-05-04 MX MX2023013021A patent/MX2023013021A/es unknown
- 2022-05-04 US US18/289,559 patent/US20250084154A1/en active Pending
- 2022-05-04 JP JP2023568153A patent/JP2024521638A/ja active Pending
- 2022-05-04 EP EP22719601.1A patent/EP4333981A1/en active Pending
- 2022-05-04 IL IL308223A patent/IL308223A/en unknown
- 2022-05-04 CA CA3215452A patent/CA3215452A1/en active Pending
- 2022-05-04 WO PCT/EP2022/061970 patent/WO2022233931A1/en not_active Ceased
- 2022-05-04 AU AU2022270356A patent/AU2022270356A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022270356A1 (en) | 2023-09-14 |
| JP2024521638A (ja) | 2024-06-04 |
| US20250084154A1 (en) | 2025-03-13 |
| EP4333981A1 (en) | 2024-03-13 |
| IL308223A (en) | 2024-01-01 |
| KR20240005856A (ko) | 2024-01-12 |
| WO2022233931A1 (en) | 2022-11-10 |
| CA3215452A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190115A1 (es) | Anticuerpos vista antihumanos y su uso | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| ECSP10010322A (es) | Anticuerpos contra el virus de la influenza y métodos de uso de los mismos | |
| CL2019003143A1 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso. | |
| ES2617920T3 (es) | Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2 | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| CR10068A (es) | Anticuerpos anti mn y métodos para su utilización | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| PE20231376A1 (es) | Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos | |
| BR112016008409A2 (pt) | Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2 | |
| MX2023013021A (es) | Inhibicion de trampas extracelulares. | |
| MX2021001902A (es) | Anticuerpos que se unen a histona 2a y/o 4 citrulinada. | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| CR20210180A (es) | Moduladores de la expresión de pnpla3 | |
| MX2022011972A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| CL2019003485A1 (es) | Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909) | |
| AR117653A1 (es) | Método para tratamiento de miastenia grave | |
| CL2018003167A1 (es) | Selección de cepas bacterianas útiles en el tratamiento de alergias. | |
| UY38393A (es) | Anticuerpos contra bcma soluble | |
| MX392348B (es) | Anticuerpo anti cd43 y uso del mismo para tratamiento del cáncer. | |
| CL2021000107A1 (es) | Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma | |
| CL2021000531A1 (es) | Métodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. | |
| CL2020002294A1 (es) | Uso de un anticuerpo anti–p–selectina | |
| CL2024001422A1 (es) | Uso de anticuerpo anti masp-2 para tratar sobrecarga de fluidos después de un trasplante. |